Market Closed - Xetra 11:35:09 2024-05-21 EDT After market 15:48:07
68.45 EUR +0.51% Intraday chart for MorphoSys AG 68.18 -0.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15 DP
Novartis: presents results of tender offer for MorphoSysy CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold MT
MORPHOSYS : UBS reiterates its Neutral rating ZD
European Equities Traded in the US as American Depositary Receipts Decline MT
MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
MORPHOSYS : UBS remains Neutral ZD
Novartis target Morphosys multiplies losses - takeover schedule stands DP
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
Morphosys says takeover by Novartis on course after report of drug safety concern RE
Health Care Slips on Risk Bias -- Health Care Roundup DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares DJ
Novartis: MorphoSys Board recommends tender offer CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins MT
Morphosys management bodies recommend acceptance of Novartis takeover bid DP
Novartis begins tender offer for cancer-focused MorphoSys RE
Novartis Launches Tender Offer for Germany's MorphoSys MT
Novartis initiates tender offer for MorphoSys CF
Novartis begins tender offer for cancer-focused MorphoSys RE
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance MT
INDEX-MONITOR: Morphosys and Bilfinger in the MDax as of today - Dax unchanged DP
Chart MorphoSys AG
More charts
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.1 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.78%
Consensus
  1. Stock Market
  2. Equities
  3. MOR Stock
  4. News MorphoSys AG
  5. Novartis Launches Tender Offer for Germany's MorphoSys
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW